Broad-spectrum antibiotics administered to patients with severe COVID-19 pneumonia pose a risk of infection caused by Clostridioides difficile. This risk is reduced mainly by strict hygiene measures and early de-escalation of antibiotic therapy. Recently, oral vancomycin prophylaxis (OVP) has also been discussed. This retrospective study aimed to assess the prevalence of C. difficile in critical COVID-19 patients staying in an intensive care unit of a tertiary hospital department of anesthesiology, resuscitation, and intensive care from November 2020 to May 2021 and the rates of vancomycin-resistant enterococci (VRE) after the introduction of OVP and to compare the data with those from controls in the pre-pandemic period (November 2018 to May 2019). During the COVID-19 pandemic, there was a significant increase in toxigenic C. difficile rates to 12.4% of patients, as compared with 1.6% in controls. The peak rates were noted in February 2021 (25% of patients), immediately followed by initiation of OVP, changes to hygiene precautions, and more rapid de-escalation of antibiotic therapy. Subsequently, toxigenic C. difficile detection rates started to fall. There was a nonsignificant increase in VRE detected in non-gastrointestinal tract samples to 8.9% in the COVID-19 group, as compared to 5.3% in the control group. Molecular analysis confirmed mainly clonal spread of VRE.

Department of Anesthesiology Resuscitation and Intensive Care University Hospital Olomouc 1 P Pavlova 6 779 00 Olomouc Czech Republic

Department of Medical Biophysics Faculty of Medicine and Dentistry Palacky University Olomouc Hnevotinska 3 779 00 Olomouc Czech Republic

Department of Microbiology Faculty of Medicine and Dentistry Palacky University Olomouc Hnevotinska 3 779 00 Olomouc Czech Republic

Department of Microbiology University Hospital Olomouc 1 P Pavlova 6 779 00 Olomouc Czech Republic

Zobrazit více v PubMed

World Health Organization Clinical Management of COVID-19: Interim Guidance, 27 May 2020. [(accessed on 29 August 2021)]. Available online: https://apps.who.int/iris/handle/10665/332196.

Martín-Loeches I., Sanchez-Corral A., Diaz E., Granada R., Zaragoza R., Villavicencio C., Albaya A., Cerdá E., Catalán R., Luque P., et al. Community-Acquired Respiratory Coinfection in Critically Ill Patients with Pandemic 2009 Influenza A(H1N1) Virus. Chest. 2011;139:555–562. doi: 10.1378/chest.10-1396. PubMed DOI

Manohar P., Loh B., Nachimuthu R., Hua X., Welburn S., Leptihn S. Secondary Bacterial Infections in Patients with Viral Pneu-monia. Front. Med. 2020;7:420. doi: 10.3389/fmed.2020.00420. PubMed DOI PMC

Brown K., Langford B., Schwartz K., Diong C., Garber G., Daneman N. Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study. Clin. Infect. Dis. 2021;72:836–844. doi: 10.1093/cid/ciaa124. PubMed DOI PMC

Ponce-Alonso M., Sáez de la Fuente J., Rincón-Carlavilla A., Moreno-Nunez P., Martínez-García L., Escudero-Sánchez R., Pintor R., García-Fernández S., Cobo J. Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection. Infect. Control. Hosp. Epidemiol. 2021;42:406–410. doi: 10.1017/ice.2020.454. PubMed DOI PMC

Bentivegna E., Alessio G., Spuntarelli V., Luciani M., Santino I., Simmaco M., Martelletti P. Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection. Am. J. Infect. Control. 2021;49:640–642. doi: 10.1016/j.ajic.2020.09.010. PubMed DOI PMC

Ochoa-Hein E., Rajme-López S., Rodríguez-Aldama J., Huertas-Jiménez M., Chávez-Ríos A., de Paz-García R., Haro-Osnaya A., González-Colín K., González-González R., González-Lara M., et al. Substantial reduction of healthcare facility-onset Clostridioides difficile infection (HO-CDI) rates after conversion of a hospital for exclusive treatment of COVID-19 patients. Am. J. Infect. Control. 2021;49:966–968. doi: 10.1016/j.ajic.2020.12.008. PubMed DOI PMC

Luo Y., Grinspan L., Fu Y., Adams-Sommer V., Willey D., Patel G., Grinspan A. Hospital-onset Clostridioides difficile infections during the COVID-19 pandemic. Infect. Control Hosp. Epidemiol. 2020;1–2 doi: 10.1017/ice.2020.1223. PubMed DOI PMC

Allegretti J., Nije C., McClure E., Redd W., Wong D., Zhou J., Bazarbashi A., McCarty T., Hathorn K., Shen L., et al. Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 201 9. JGH Open. 2021;5:622–625. doi: 10.1002/jgh3.12497. PubMed DOI PMC

Sandhu A., Tillotson G., Polistico J., Salimnia H., Cranis M., Moshos J., Cullen L., Jabbo L., Diebel L., Chopra T. Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020. Emerg. Infect. Dis. 2020;26:2272–2274. doi: 10.3201/eid2609.202126. PubMed DOI PMC

Lewandowski K., Rosołowski M., Kaniewska M., Kucha P., Meler A., Wierzba W., Rydzewska G. Clostridioides difficile infection in coronavirus disease 2019: An underestimated problem? Pol. Arch. Intern. Med. 2020;131:121–127. doi: 10.20452/pamw.15715. PubMed DOI

European Centre for Disease Prevention and Control . ECDC Annual Epidemiological Report for 2016. ECDC; Stockholm, Sweden: 2018. [(accessed on 29 August 2021)]. Healthcare-associated infections: Clostridium difficile. Available online: https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-clostridium-difficile-infections-annual.

Lessa F., Mu Y., Bamberg W., Beldavs Z., Dumyati G., Dunn J., Farley M., Holzbauer S., Meek J., Phipps E., et al. Burden of Clostridium difficile Infection in the United States. N. Engl. J. Med. 2015;372:825–834. doi: 10.1056/NEJMoa1408913. PubMed DOI PMC

Tariq R., Laguio-Vila M., Tahir M., Orenstein R., Pardi D., Khanna S. Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: A systematic review and meta-analysis. Ther. Adv. Gastroenterol. 2021;23:1756284821994046. doi: 10.1016/S0016-5085(19)39215-7. PubMed DOI PMC

Isaac S., Scher J., Djukovic A., Jiménez N., Littman D., Abramson S., Pamer E., Ubeda C. Short- and long-term effects of oral van-comycin on the human intestinal microbiota. J. Antimicrob. Chemother. 2016;72:128–136. doi: 10.1093/jac/dkw383. PubMed DOI PMC

Hricová K., Štosová T., Kučová P., Fišerová K., Bardoň J., Kolář M. Analysis of Vancomycin-Resistant Enterococci in Hemato-Oncological Patients. Antibiotics. 2020;9:785. doi: 10.3390/antibiotics9110785. PubMed DOI PMC

Tenover F., Arbeit R., Goering R., Mickelsen P., Murray B., Persing D., Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J. Clin. Microbiol. 1995;33:2233–2239. doi: 10.1128/jcm.33.9.2233-2239.1995. PubMed DOI PMC

WHO Collaborating Centre for Drug Statistics Methodology . ATC Classification Index with DDDs, 2021. WHO Collaborating Centre for Drug Statistics Methodology; Oslo, Norway: 2020.

Yacyshyn B. Pathophysiology of Clostridium difficile-Associated Diarrhea. [(accessed on 29 August 2021)];Gastroenterol. Hepatol. 2016 12:558–560. Available online: https://pubmed.ncbi.nlm.nih.gov/27917094. PubMed PMC

Zuo T., Zhang F., Lui G.C., Yeoh Y.K., Li A.Y., Zhan H., Wan Y., Chung A.C., Cheung C.P., Chen N., et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159:944–955.e8. doi: 10.1053/j.gastro.2020.05.048. PubMed DOI PMC

Hazel K., Skally M., Glynn E., Foley M., Burns K., O’Toole A., Boland K., Fitzpatrick F. The other ‘C’: Hospital-acquired Clos-tridioides difficile infection during the coronavirus disease 2019 (COVID-19) pandemic. Infect. Control Hosp. Epidemiol. 2021;1–2:1–2. doi: 10.1017/ice.2021.3. PubMed DOI PMC

Kaafarani H.M. COVID-19: Gastrointestinal Symptoms and Complications. [(accessed on 4 August 2021)]. Available online: https://www.uptodate.com/contents/covid-19-gastrointestinal-symptoms-and-complications/print.

Cheung K., Hung I., Chan P., Lung K., Tso E., Liu R., Ng Y., Chu M., Chung T., Tam A., et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from a Hong Kong Cohort: Systematic Review and Meta-analysis. Gastroenterology. 2020;159:81–95. doi: 10.1053/j.gastro.2020.03.065. PubMed DOI PMC

Silva F., Brito B., Santos M., Marques H., Silva Júnior R., Carvalho L., Vieira E., Oliveira M., Melo F. COVID-19 gastrointestinal manifestations: A systematic review. Rev. Da Soc. Bras. De Med. Trop. 2020;53 doi: 10.1590/0037-8682-0714-2020. PubMed DOI PMC

D’Amico F., Baumgart D., Danese S., Peyrin-Biroulet L. Diarrhea during COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin. Gastroenterol. Hepatol. 2020;18:1663–1672. doi: 10.1016/j.cgh.2020.04.001. PubMed DOI PMC

Norén T. Clostridium Difficile and the Disease it Causes. Clostridium Difficile. Volume 646. Humana Press; Totowa, NJ, USA: 2010. pp. 9–35. PubMed DOI

Govil D., Pal D. Gastrointestinal Motility Disorders in Critically Ill. Indian J. Crit. Care Med. 2020;24:S179–S182. doi: 10.5005/jp-journals-10071-23614. PubMed DOI PMC

Davies K., Longshaw C., Davis G., Bouza E., Barbut F., Barna Z., Delmée M., Fitzpatrick F., Ivanova K., Kuijper E., et al. Underdiagnosis of Clostridium difficile across Europe: The European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID) Lancet Infect. Dis. 2014;14:1208–1219. doi: 10.1016/S1473-3099(14)70991-0. PubMed DOI

Sieswerda E., de Boer M., Bonten M., Boersma W., Jonkers R., Aleva R., Kullberg B., Schouten J., van de Garde E., Verheij T., et al. Recommendations for antibacterial therapy in adults with COVID-19—An evidence based guideline. Clin. Microbiol. Infect. 2021;27:61–66. doi: 10.1016/j.cmi.2020.09.041. PubMed DOI PMC

National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. [(accessed on 1 August 2021)]; Available online: https://www.covid19treatmentguidelines.nih.gov/ PubMed

Kalil A., Metersky M., Klompas M., Muscedere J., Sweeney D., Palmer L., Napolitano L., O’Grady N., Bartlett J., Carratalà J., et al. Management of Adults with Hospi-tal-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016;63:e61–e111. doi: 10.1093/cid/ciw353. PubMed DOI PMC

Uvizl R., Adamus M., Cerny V., Dusek L., Jarkovsky J., Sramek V., Matejovic M., Stourac P., Kula R., Malaska J., et al. Patient survival, predictive factors and disease course of severe sepsis in Czech intensive care units: A multicentre, retrospective, observational study. Biomed. Pap. 2016;160:287–297. doi: 10.5507/bp.2015.052. PubMed DOI

Herkel T., Uvízl R., Doubravská L., Adamus M., Gabrhelík T., Sedlakova M.H., Kolář M., Hanulík V., Pudová V., Langová K., et al. Epidemiology of hospital-acquired pneumonia: Results of a Central European multicenter, prospective, observational study compared with data from the European region. [(accessed on 29 August 2021)];Biomed. Pap. J. Fac. Med. Dent. Palacky Univ. Olomouc. 2016 160:448–455. doi: 10.5507/bp.2016.014. Available online: http://www.medvik.cz/link/bmc16028823. PubMed DOI

Rawson T., Moore L., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., Satta G., Cooke G., Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin. Infect. Dis. 2020;71:2459–2468. doi: 10.1093/cid/ciaa530. PubMed DOI PMC

Langford B., So M., Raybardhan S., Leung V., Westwood D., MacFadden D., Soucy J., Daneman N. Bacterial co-infection and sec-ondary infection in patients with COVID-19: A living rapid review and meta-analysis: A living rapid review and meta-analysis. Clin. Microbiol. Infect. 2020;26:1622–1629. doi: 10.1016/j.cmi.2020.07.016. PubMed DOI PMC

Lansbury L., Lim B., Baskaran V., Lim W. Co-infections in people with COVID-19: A systematic review and meta-analysis: A systematic review and meta-analysis. J. Infect. 2020;81:266–275. doi: 10.1016/j.jinf.2020.05.046. PubMed DOI PMC

Hughes S., Troise O., Donaldson H., Mughal N., Moore L. Bacterial and fungal coinfection among hospitalized patients with COVID-19: A retrospective cohort study in a UK secondary-care setting. Clin. Microbiol. Infect. 2020;26:1395–1399. doi: 10.1016/j.cmi.2020.06.025. PubMed DOI PMC

Garcia-Vidal C., Sanjuan G., Moreno-García E., Puerta-Alcalde P., Garcia-Pouton N., Chumbita M., Fernandez-Pittol M., Pitart C., Inciarte A., Bodro M., et al. Incidence of co-infections and superinfections in hospitalised patients with COVID-19: A retrospective cohort study. Clin. Microbiol. Infect. 2021;27:83–88. doi: 10.1016/j.cmi.2020.07.041. PubMed DOI PMC

Vaughn V., Gandhi T., Petty L., Patel P., Prescott H., Malani A., Ratz D., McLaughlin E., Chopra V., Flanders S. Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study. Clin. Infect. Dis. 2021;72:e533–e541. doi: 10.1093/cid/ciaa1239. PubMed DOI PMC

Youngs J., Wyncoll D., Hopkins P., Arnold A., Ball J., Bicanic T. Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with influenza. J. Infect. 2020;81:e55–e57. doi: 10.1016/j.jinf.2020.06.056. PubMed DOI PMC

Clancy C., Nguyen M. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clin. Infect. Dis. 2020;71:2736–2743. doi: 10.1093/cid/ciaa524. PubMed DOI PMC

Aggarwal S., Garcia-Telles N., Aggarwal G., Lavie C., Lippi G., Henry B. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis. 2020;7:91–96. doi: 10.1515/dx-2020-0046. PubMed DOI

Guan W., Ni Z., Hu Y., Liang W., Ou C., He J., Liu L., Shan H., Lei C., Hui D., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. PubMed DOI PMC

Pan L., Mu M., Yang P., Sun Y., Wang R., Yan J., Li P., Hu B., Wang J., Hu C., et al. Clinical Characteristics of COVID-19 Patients with Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am. J. Gastroenterol. 2020;115:766–773. doi: 10.14309/ajg.0000000000000620. PubMed DOI PMC

Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19. N. Engl. J. Med. 2020;382:1787–1799. doi: 10.1056/NEJMoa2001282. PubMed DOI PMC

Chen T., Wu D., Chen H., Yan W., Yang D., Chen G., Ma K., Xu D., Yu H., Wang H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retro-spective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091. PubMed DOI PMC

Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. PubMed DOI PMC

Wang Z., Yang B., Li Q., Wen L., Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin. Infect. Dis. 2020;71:769–777. doi: 10.1093/cid/ciaa272. PubMed DOI PMC

Borba M., Val F., Sampaio V., Alexandre M., Melo G., Brito M., Mourão M., Brito-Sousa J., Baía-da-Silva D., Guerra M., et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Jama Netw. Open. 2020;3:e208857. doi: 10.1001/jamanetworkopen.2020.8857. PubMed DOI

Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. PubMed DOI PMC

Zhao X., Xu X., Yin H., Hu Q., Xiong T., Tang Y., Yang A., Yu B., Huang Z. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: A retrospective study. BMC Infect. Dis. 2020;20:311. doi: 10.1186/s12879-020-05010-w. PubMed DOI PMC

Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7. PubMed DOI PMC

Pedersen H.P., Hildebrandt T., Poulsen A., Uslu B., Knudsen H.H., Roed J., Poulsen T.D., Nielsen H.B. Initial experiences from patients with COVID-19 on ventilatory support in Denmark. Dan. Med. J. 2020;67:A04200232. PubMed

Alhazzani W., Møller M., Arabi Y., Loeb M., Gong M., Fan E., Oczkowski S., Levy M., Derde L., Dzierba A., et al. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19): Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Intensive Care Med. 2020;46:854–887. doi: 10.1007/s00134-020-06022-5. PubMed DOI PMC

Kluge S., Janssens U., Welte T., Weber-Carstens S., Marx G., Karagiannidis C. German recommendations for critically ill patients with COVID 19. Med. Klin.—Intensivmed. Und Notfallmedizin. 2020;115:111–114. doi: 10.1007/s00063-020-00689-w. PubMed DOI PMC

Strategies to Prevent Clostridioides difficile Infection in Acute Care Facilities. [(accessed on 29 August 2021)]; Available online: https://www.cdc.gov/hai/prevent/cdi-prevention-strategies.html.

Johnson S., Brown S., Priest D. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility–Onset Clostridioides difficile Infection in Targeted Patients during Systemic Antibiotic Exposure. Clin. Infect. Dis. 2020;71:1133–1139. doi: 10.1093/cid/ciz966. PubMed DOI

Ganetsky A., Han J., Hughes M., Babushok D., Frey N., Gill S., Hexner E., Loren A., Luger S., Mangan J., et al. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. Clin. Infect. Dis. 2019;68:2003–2009. doi: 10.1093/cid/ciy822. PubMed DOI PMC

Babar S., El Kurdi B., El Iskandarani M., Haddad I., Imam Z., Alomari M., Myers J., Moorman J. Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: A systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2020;41:1302–1309. doi: 10.1017/ice.2020.277. PubMed DOI

Van Hise N., Bryant A., Hennessey E., Crannage A., Khoury J., Manian F. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents: Table 1. Clin. Infect. Dis. 2016;63:651–653. doi: 10.1093/cid/ciw401. PubMed DOI

Carignan A., Poulin S., Martin P., Labbé A., Valiquette L., Al-Bachari H., Montpetit L., Pépin J. Efficacy of Secondary Prophylaxis with Vancomycin for Preventing Recurrent Clostridium difficile Infections. Am. J. Gastroenterol. 2016;111:1834–1840. doi: 10.1038/ajg.2016.417. PubMed DOI

Splinter L., Kerstenetzky L., Jorgenson M., Descourouez J., Leverson G., Saddler C., Smith J., Safdar N., Redfield R. Vancomycin Prophylaxis for Prevention of Clostridium difficile Infection Recurrence in Renal Transplant Patients. Ann. Pharma-Cotherapy. 2017;52:113–119. doi: 10.1177/1060028017727756. PubMed DOI

Papic N., Maric L., Vince A. Efficacy of oral vancomycin in primary prevention of Clostridium Difficile infection in elderly patients treated with systemic antibiotic therapy. Infect. Dis. 2018;50:483–486. doi: 10.1080/23744235.2018.1425551. PubMed DOI

Morrisette T., Van Matre A., Miller M., Mueller S., Bajrovic V., Abidi M., Benamu E., Kaiser J., Barber G., Chase S., et al. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hemato-poietic Stem Cell Transplantation and Hematologic Malignancy Population. Biol. Blood Marrow Transplant. 2019;25:2091–2097. doi: 10.1016/j.bbmt.2019.06.021. PubMed DOI

Knight E., Schiller D., Fulman M., Rastogi R. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Clos-tridium difficile Recurrence. J. Pharm. Pract. 2020;33:633–639. doi: 10.1177/0897190019825994. PubMed DOI

McDonald L., Gerding D., Johnson S., Bakken J., Carroll K., Coffin S., Dubberke E., Garey K., Gould C., Kelly C., et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) Clin. Infect. Dis. 2018;66:e1–e48. doi: 10.1093/cid/cix1085. PubMed DOI PMC

Gonzales M., Pepin J., Frost E., Carrier J., Sirard S., Fortier L., Valiquette L. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect. Dis. 2010;10:363. doi: 10.1186/1471-2334-10-363. PubMed DOI PMC

Johnson S. Editorial Commentary: Potential Risks and Rewards with Prophylaxis for Clostridium difficile Infection. Clin. Infect. Dis. 2016;63:654–655. doi: 10.1093/cid/ciw424. PubMed DOI

Abujamel T., Cadnum J., Jury L., Sunkesula V., Kundrapu S., Jump R., Stintzi A., Donskey C., Paredes-Sabja D. Defining the Vul-nerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole. PLoS ONE. 2013;8:e76269. doi: 10.1371/journal.pone.0076269. PubMed DOI PMC

Lewis B., Buffie C., Carter R., Leiner I., Toussaint N., Miller L., Gobourne A., Ling L., Pamer E. Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection with Oral Vancomycin Compared with Metronidazole. J. Infect. Dis. 2015;212:1656–1665. doi: 10.1093/infdis/jiv256. PubMed DOI PMC

Johnson S. Treatment of Asymptomatic Clostridium difficile Carriers (Fecal Excretors) with Vancomycin or Metronidazole. Ann. Intern. Med. 1992;117:297–302. doi: 10.7326/0003-4819-117-4-297. PubMed DOI

Kampmeier S., Tönnies H., Correa-Martinez C., Mellmann A., Schwierzeck V. A nosocomial cluster of vancomycin resistant enterococci among COVID-19 patients in an intensive care unit. Antimicrob. Resist. Infect. Control. 2020;9:154. doi: 10.1186/s13756-020-00820-8. PubMed DOI PMC

Correa-Martinez C.L., Stollenwerk V.B., Kossow A., Schaumburg F., Mellmann A., Kampmeier S. Risk Factors for Long-Term Vancomycin-Resistant Enterococci Persistence—A Prospective Longitudinal Study. Microorganisms. 2019;7:400. doi: 10.3390/microorganisms7100400. PubMed DOI PMC

Bacterial Community- and Hospital-Acquired Pneumonia in Patients with Critical COVID-19-A Prospective Monocentric Cohort Study

Bacterial Resistance to Antibiotics and Clonal Spread in COVID-19-Positive Patients on a Tertiary Hospital Intensive Care Unit, Czech Republic

Bacterial Infections, Antimicrobial Resistance and Antibiotic Therapy

Pulmonary Complications after COVID-19